Trial document



drksid header

  DRKS00000315

Trial Description

start of 1:1-Block title

Title

Placebo controlled fMRT assessment
of the effects of the cannabinoid receptor agonist
dronabinol (THC) on pain associated brain activation

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Dronabinol is the chemical designation for THC (tetrahydrocannabinol), one of the active components of the hemp plant (Cannabis sativa). Dronabinol is used for therapeutic purposes in anorexia due to severe chronic diseases, and for nausea and vomiting caused by chemotherapy. Another application of cannabis is the pain therapy.
We want to examine how Dronabinol acts on pain processing in the brain and compare this with its effects on the so-called reward system. For this purpose subjects will receive either dronabinol or placebo administered on two separate study days. To capture the effects of dronabinol on pain, an experimental pain model is used which is based on painful irritation of the nasal mucosa with gaseous carbon dioxide. In addition, to verify the effect of THC on the reward system, hydrogen sulphide and vanilla smell will be applied.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Aim of this study is to investigate the effects of dronabinol on the activation of brain-areas responsible for the identification and quantification of pain stimuli and their affective-hedonic assessment . In a preliminary work the effects of opioids could be clearly differentiated in reducing the sensory or the affective component of pain. The thereby used imaging procedure fMRI should make this possible in the present study for THC.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00000315
  •   2010/06/22
  •   [---]*
  •   yes
  •   Approved
  •   334/08, Ethikkommission des Fachbereichs Humanmedizin der Johann-Wolfgang-Goethe-Universität Frankfurt am Main
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   U1111-1115-5572 
  •   2008-006881-27 
  •   4034806 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   healthy volunteers
  •   R52.0 -  Acute pain
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Study participants receive a single oral dose of 20mg tetrahydrocannabinol.
    Prior to administration of the study medication and 2 hours after administration a one hour-lasting MRI measurement for identification of brain areas activated by the pain and odor stimuli is conducted.
  •   Study participants receive a single oral dose of placebo.
    Prior to administration of the study medication and 2 hours after administration a one hour-lasting MRI measurement for identification of brain areas activated by the pain and odor stimuli is conducted.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Double or multiple blind
  •   [---]*
  •   Placebo
  •   Other
  •   Crossover
  •   I
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Intensity of brain activation during nociceptive stimulation measured 2 hours after dronabinol application using functional magnetic resonance imaging

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Topographic distribution of the fMRI brain responses to nociceptive stimulation under dronabinol

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2010/07/01
  •   36
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   50   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

• Healthy men and women aged 18-50 years
• Body mass index (BMI) in the range of 18 kg/m2 and 30 kg/m2
• unremarkable medical history, especially no heart and circulatory diseases, mental medical history
• Healthy as determined by medical history, physical examination including vital signs and clinical laboratory test results
• Women of childbearing age must be sterile or postmenopausal or must apply two appropriate measures of contraception (e.g. oral hormonal contraceptive plus intrauterine device) in accordance with Note 3 of the Note for guidance on non-clinical studies saftey for the Conduct of human clinical trials for pharmaceuticals (CPMP / ICH / 286 / 95 modification) (double contraception).
• Signed informed consent after information about the benefits and risks of the trial and insurance

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

• Participation in another clinical study within the last 30 days before study
• Simultaneous participation in another clinical trial
• History or current evidence of abuse of any drug substance, licit or illicit, including alcohol (urine drug screen)
• currently using of any prescription medication
• Hypersensitivity to the active substance or any of the other ingredients
• Epilepsy, a tendency to seizures
• Cardiovascular diseases
• Depression, bipolar disorder, schizophrenia and other psychiatric disorders in the medical history
• impaired liver function
• renal impairment
• Pregnancy (positive pregnancy test in urine at “screening” or at the beginning of the study) and breast-feeding
• Diseases or other criteria that make an MRI measurement impossible:
• Pacemakers
• neurostimulator or drug pump
• Metal parts in the body (e.g. chips, clips or staples after surgery, including: metal fragments in the body)
• claustrophobia

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Klinikum der J.W.Goethe-Universität Frankfurt
    • Mr.  Prof. Dr.  Joseph   Pfeilschifter 
    • Theodor-Stern-Kai 7
    • 60590  Frankfurt
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Institut für Klinische Pharmakologie Klinikum der J.W.Goethe-Universität Frankfurt
    • Mr.  Prof. Dr.  Jörn  Lötsch 
    • Theodor-Stern-Kai 7
    • 60590  Frankfurt
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Institut für Klinische Pharmakologie Klinikum der J.W. Goethe-Universität Frankfurt
    • Ms.  Carmen  Walter 
    • Theodor-Stern-Kai7
    • 60590  Frankfurt
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Deutsche Forschungsgemeinschaft e.V.
    • Kennedyallee 40
    • 53175  Bonn
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
  • start of 1:1-Block address otherSupport
    • Institut für Klinische Pharmakologie Klinikum der J.W.Goethe-Universität Frankfurt
    • Mr.  Prof. Dr.  Jörn  Lötsch 
    • Theodor-Stern-Kai 7
    • 60590  Frankfurt
    • Germany
    end of 1:1-Block address otherSupport
    start of 1:1-Block address contact otherSupport
    end of 1:1-Block address contact otherSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2011/12/31
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.